Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have been used as suggested for heavily pretreated molecularly selected patients with NSCLC [19–22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.